Order Article Reprints
Journal: Curr. Oncol., 2019
Volume: 26
Number: 4809
Article:
Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib
Authors:
by
Barbara Melosky, Parneet Cheema and Geoffrey Liu
Link:
https://www.mdpi.com/1718-7729/26/1/4809
MDPI offers high quality article reprints with convenient shipping to destinations worldwide. Each reprint features a 270 gsm bright white cover
and 105 gsm premium white paper, bound with two stitches for durability and printed in full color. The cover design is customized to your article
and designed to be complimentary to the journal.